Study on the safety and efficacy of the new coronavirus (COVID-19) vaccine in HIV-infected patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050922

Enrollment

Unknown

Registered

2021-09-08

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human immunodeficiency virus infection

Interventions

HIV infection group:Nil

healthy control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. HIV infection group: (1) HIV positive diagnosis is clear; (2) Aged 18-80 years; (3) Have been vaccinated against the new crown; (4) Voluntarily participate in the project. 2. Healthy control group: (1) HIV negative; (2) Aged 18-80 years; (3) The new crown vaccination has been completed; (4) Voluntarily participate in the project.

Exclusion criteria

Exclusion criteria: Previous laboratory-confirmed new crown, a history of contact with a confirmed new crown case, and contraindications to vaccination.

Design outcomes

Primary

Measure	Time frame
anti-SARS-CoV-2 antibody;SARS-CoV-2-specific memory B cell;	—

Secondary

Measure	Time frame
HIV viral load;CD4+T cell count;	—

Countries

China

Contacts

Public ContactRen Hong

Chongqing Medical University

renhong0531@cqmu.edu.cn+86 23 63693029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026